Letermovir to prevent CMV in children after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests if the drug letermovir can prevent a common virus (CMV) in children who have certain blood disorders and are getting a stem cell transplant. It aims to keep you safer during recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with either EBV-positive T/NK lymphoproliferative disease or a type of EBV-associated HLH that did not get better with treatment.
- This is your first stem cell transplant (you have not had one before), and you are getting it at Beijing Children's Hospital.
- You are under 18 years old.
- You tested positive for CMV before the transplant.
- You have at least one high-risk factor for CMV, such as a partially matched donor, use of a certain anti-rejection drug, long-term steroids, or a positive CMV test shortly before transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
This study tests an oral antiviral medication called letermovir to see if it safely prevents CMV (a common virus) in children who have recently had a kidney transplant. It's for children ages typically 4 weeks to about a year post-transplant, with stable kidney function and no current CMV infection.
Hear when a new EBV-associated T/NK-cell Lymphoproliferative Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.